E2 fusion protein as well as coding gene and application thereof
By developing E2 fusion protein and its encoding gene, and using its helicase activity to screen anti-HPV drugs, the problem of lack of specific anti-HPV drugs in the prior art was solved, and effective treatment of HPV16 was achieved.
Patent Information
- Application Number
- CN202411307837.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-19
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2044-09-19
AI Technical Summary
The existing treatment methods for HPV infection lack specific antiviral drugs, making it difficult to effectively control the treatment of HPV16 high-risk viruses.
E2 fusion proteins and their encoding genes are developed to form proteins with helicase activity by fusion with tags or amino acid modifications, and to screen anti-HPV drugs using it to reduce helicase activity.
By detecting whether the drug to be tested reduces the helicase activity of the E2 protein or E2 fusion protein, potential anti-HPV drugs are screened out, providing specific therapeutic targets for HPV16, significantly improving the treatment efficiency.
Smart Images

Figure HDA0005049786520000011 
Figure HDA0005049786520000012 
Figure HDA0005049786520000021
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology, and specifically relates to E2 fusion protein and its encoding gene and application. Technical Background
[0002] Human papillomavirus (HPV) belongs to the genus Papillomavirus A of the family Papovaviridae. It is a spherical DNA virus that can cause proliferation of squamous epithelial cells in the skin and mucous membranes of the human body. At present, more than 130 types of human papillomavirus have been isolated, and different types cause different clinical manifestations, such as common warts, genital warts (condyloma acuminatum) and other symptoms. HPV16 is a high-risk HPV, and its infection is closely related to the occurrence of cervical cancer.
[0003] The HPV early region encodes seven viral nonstructural proteins: E1, E2, E1^E4, E5, E6, E7 and E8^E2, of which E2 is an E1 auxiliary protein. Both are essential for tumor virus DNA replication. In addition, E2 also acts as a viral transcription activator or repressor, depending on its binding position, and participates in viral genome separation during mitosis. Current research generally believes that E1 protein has helicase activity, and E2 protein serves as an auxiliary and regulatory protein of E1 protein.
[0004] Currently, the treatment methods for warts caused by HPV infection generally include drug therapy and physical therapy. Drug therapy includes immunomodulators, interferon, acyclovir, etc. These drugs inhibit HPV infection by improving the body's immunity or exerting a broad-spectrum antiviral effect. However, antiviral drugs specific for HPV infection have not yet been launched on the market. Therefore, the development of highly effective and specific anti-HPV drugs is imminent. Summary of the invention
[0005] The purpose of the present invention is to screen anti-human papillomavirus drugs.
[0006] The present invention first protects the E2 fusion protein, which can be the following a1) or a2) or a3) or a4):
[0007] a1) is formed by fusion of E2 protein and a tag; the amino acid sequence of the E2 protein is shown in SEQ ID NO: 1 from position 1 to position 365 from the N-terminus;
[0008] a2) a fusion protein obtained by connecting a tag to the N-terminus and / or C-terminus of the protein shown in a1);
[0009] a3) a protein having helicase activity obtained by substituting and / or deleting and / or adding one or more amino acid residues in the amino acid sequence of the protein shown in a1) or a2);
[0010] a4) A protein having an amino acid sequence homology of 80% or more to the protein shown in a1) or a2) and having helicase activity.
[0011] For the protein in a1) or a2) above, the tag may be specifically as shown in Table 1.
[0012] Table 1
[0013] Label Residue sequence Poly-Arg 5-6 (usually 5) RRRRR Poly-His 2-10 (usually 6) HHHHHH FLAG 8 DYKDDDDK Strep-tag II 8 WSHQ C-myc 10 EQKLISEEDL HA 9 YPYDVPDYA
[0014] The protein in a1) above, the E2 protein and the tag can be connected via a connecting peptide to form an E2 fusion protein.
[0015] The E2 protein and the tag can be connected through a connecting peptide. Specifically, the last amino acid residue of the E2 protein (i.e., the 365th amino acid residue from the N-terminus of SEQ ID NO: 1) is connected to the first amino acid residue of the connecting peptide, and the last amino acid residue of the connecting peptide is connected to the first amino acid residue of the tag (such as the HA tag). The amino acid sequence of the HA tag can be shown as the 372nd to 380th amino acid residue from the N-terminus of SEQ ID NO: 1.
[0016] Furthermore, the connecting peptide may be a GGSSGG connecting peptide.
[0017] In some embodiments of the present application, the amino acid sequence of the GGSSGG connecting peptide may be as shown in SEQ ID NO: 1, positions 366 to 371 from the N-terminus. The first amino acid residue of the GGSSGG connecting peptide is the 366th amino acid residue from the N-terminus of SEQ ID NO: 1, and the last amino acid residue of the GGSSGG connecting peptide is the 371st amino acid residue from the N-terminus of SEQ ID NO: 1.
[0018] The above connection can be achieved by forming a peptide bond through dehydration condensation of two amino acid residues.
[0019] In a1), the amino acid sequence of the E2 fusion protein may be as shown in SEQ ID NO:1.
[0020] In the protein described in a3) above, the substitution and / or deletion and / or addition of one or several amino acid residues is a substitution and / or deletion and / or addition of no more than 10 amino acid residues.
[0021] The protein in a3) above can be artificially synthesized, or its encoding gene can be synthesized first and then expressed biologically.
[0022] The coding gene of the protein in a3) above can be obtained by deleting one or several codons of amino acid residues in the DNA sequence shown in SEQ ID NO: 2 or SEQ ID NO: 3, and / or performing missense mutation of one or several base pairs, and / or connecting the coding sequence of the tag shown in Table 1 to its 5′ end and / or 3′ end.
[0023] The present invention also protects a nucleic acid molecule encoding any of the above-mentioned E2 fusion proteins.
[0024] The nucleic acid molecule of any of the above-mentioned E2 fusion proteins may be a DNA molecule as shown in b1) or b2) or b3) or b4) below:
[0025] b1) the coding region is a DNA molecule shown in SEQ ID NO: 2 or SEQ ID NO: 3;
[0026] b2) the nucleotide sequence is a DNA molecule shown in SEQ ID NO: 2 or SEQ ID NO: 3;
[0027] b3) a DNA molecule having 75% or more homology with the nucleotide sequence defined in b1) or b2) and encoding any of the above-mentioned E2 fusion proteins;
[0028] b4) A DNA molecule that hybridizes with the nucleotide sequence defined in b1) or b2) under stringent conditions and encodes any of the E2 fusion proteins described above.
[0029] The “nucleotide sequence having 75% or more homology with the nucleotide sequence specified in b1) or b2)” may be a DNA molecule having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% homology with the DNA molecule specified in b1) or b2) and encoding any of the above-mentioned E2 fusion proteins.
[0030] The stringent conditions are hybridization and membrane washing twice at 68°C in a 2×SSC, 0.1% SDS solution, each for 5 min, and hybridization and membrane washing twice at 68°C in a 0.5×SSC, 0.1% SDS solution, each for 15 min.
[0031] The nucleic acid molecule may be DNA, such as cDNA, genomic DNA or recombinant DNA; the nucleic acid molecule may also be RNA, such as mRNA or hnRNA.
[0032] Among them, SEQ ID NO: 2 consists of 1143 nucleotides, SEQ ID NO: 3 consists of 1143 nucleotides, and the nucleotide sequence shown in SEQ ID NO: 2 or the nucleotide sequence shown in SEQ ID NO: 3 encodes the amino acid sequence shown in SEQ ID NO: 1. In SEQ ID NO: 2, from the 5' end, positions 1 to 1095 are the E2 gene, positions 1096 to 1113 are the coding gene of the connecting peptide GGSSGG, and positions 1114 to 1140 are the coding gene of the HA tag.
[0033] A person skilled in the art can easily mutate the nucleotide sequence encoding any of the above-mentioned E2 fusion proteins by using known methods, such as directed evolution and point mutation. Those artificially modified nucleotides having 75% or higher identity with the nucleotide sequence of the E2 fusion protein of the present invention are derived from the nucleotide sequence of the present invention and are equivalent to the sequence of the present invention as long as they encode the E2 fusion protein.
[0034] The term "identity" as used herein refers to sequence similarity with a natural nucleic acid sequence. "Identity" includes nucleotide sequences that have 75% or more, or 80% or more, or 85% or more, or 90% or more, or 95% or more identity with the nucleotide sequence of the E2 fusion protein of the present invention encoding the amino acid sequence shown in SEQ ID NO: 1. Identity can be evaluated by the naked eye or by computer software. Using computer software, the identity between two or more sequences can be expressed as a percentage (%), which can be used to evaluate the identity between related sequences.
[0035] An expression cassette, recombinant vector or recombinant microorganism containing any of the above-mentioned nucleic acid molecules also falls within the protection scope of the present invention.
[0036] The recombinant vector containing any of the above-mentioned nucleic acid molecules can specifically be a recombinant plasmid obtained by inserting a nucleic acid molecule of any of the above-mentioned E2 fusion proteins into the multiple cloning site of an expression vector.
[0037] The recombinant vector containing any of the above-mentioned nucleic acid molecules can be specifically a recombinant plasmid pET-28a-HPV16E2. The recombinant plasmid pET-28a-HPV16 E2 can be specifically a recombinant plasmid obtained by replacing the small DNA fragment between the restriction endonucleases Nde I and Xho I of the vector pET-28a with the E2-YH fusion gene shown in SEQ ID NO: 3, while other nucleotide sequences remain unchanged.
[0038] The recombinant microorganism containing any of the above-mentioned nucleic acid molecules can be a recombinant microorganism obtained by transforming the recombinant vector containing any of the above-mentioned nucleic acid molecules into a starting microorganism. The starting microorganism can be Escherichia coli or Agrobacterium, etc. The Escherichia coli can be Escherichia coli BL21 (DE3).
[0039] The recombinant microorganism containing any of the above-mentioned nucleic acid molecules can be the recombinant Escherichia coli mentioned in the examples, that is, obtained by transforming the recombinant plasmid pET-28a-HPV16 E2 into Escherichia coli BL21 (DE3).
[0040] The present invention also protects the use of any of the above-mentioned E2 proteins, any of the above-mentioned E2 fusion proteins or any of the above-mentioned nucleic acid molecules, which may be the following c1) or c2):
[0041] c1) as a helicase;
[0042] c2) preparing helicase.
[0043] In the above application, the helicase may be a DNA helicase. Preferably, the substrate of the DNA helicase may be dsDNA. The nucleotide sequence of the dsDNA may be as shown in SEQ ID NO:4.
[0044] The present invention also protects the use of any of the above-mentioned E2 proteins, any of the above-mentioned E2 fusion proteins or any of the above-mentioned nucleic acid molecules, which may be the following d1) or d2):
[0045] d1) Screening of anti-human papillomavirus drugs;
[0046] d2) as a target for screening anti-human papillomavirus drugs.
[0047] In the above application, the anti-human papillomavirus drug may be podophyllotoxin.
[0048] Any of the above human papillomaviruses includes various types of human papillomaviruses.
[0049] The principle of screening anti-human papillomavirus drugs in the above application is that the anti-human papillomavirus drugs can reduce the activity of the helicase of any of the above-mentioned E2 proteins or any of the above-mentioned E2 fusion proteins. The helicase can be a DNA helicase. Preferably, the substrate of the DNA helicase can be dsDNA. Therefore, the anti-human papillomavirus drugs are screened by detecting whether the activity of the helicase is reduced.
[0050] The present invention also protects a method for screening anti-human papillomavirus drugs, which can be used to detect whether the drug to be tested can reduce the activity of the helicase of any of the above-mentioned E2 proteins or any of the above-mentioned E2 fusion proteins, and then make the following judgment: if the drug to be tested can reduce the activity of the helicase of any of the above-mentioned E2 proteins or any of the above-mentioned E2 fusion proteins, the drug to be tested is or is suspected to be an anti-human papillomavirus drug; if the drug to be tested cannot reduce the activity of the helicase of any of the above-mentioned E2 proteins or any of the above-mentioned E2 fusion proteins, the drug to be tested is not or is not suspected to be an anti-human papillomavirus drug.
[0051] Any of the above-mentioned anti-human papillomavirus drugs can be podophyllotoxin.
[0052] The present invention also protects the use of podophyllotoxin in reducing the helicase activity of any of the above-mentioned E2 proteins or any of the above-mentioned E2 fusion proteins.
[0053] Experiments have shown that the E2 protein has helicase activity, and the anti-human papillomavirus drug podophyllotoxin can inhibit the helicase activity of the E2 protein. Therefore, the E2 protein is the target of podophyllotoxin and can also be used as a target for screening anti-human papillomavirus drugs. The present invention has important application value in the process of screening anti-human papillomavirus drugs. BRIEF DESCRIPTION OF THE DRAWINGS
[0054] Figure 1 This is the polyacrylamide gel electrophoresis detection result of the protein solution obtained in step 7 of Example 1.
[0055] Figure 2 This is the result of Western blotting of the protein solution obtained in step 7 of Example 1.
[0056] Figure 3 This is the result of DNA helicase activity detection of E2 fusion protein.
[0057] Figure 4 Podophyllotoxin inhibits the DNA helicase activity of E2 fusion protein.
[0058] Figure 5 Molecular docking of the small molecule compound podophyllotoxin and E2 protein. DETAILED DESCRIPTION
[0059] The present invention is further described in detail below in conjunction with specific embodiments, and the examples provided are only for illustrating the present invention, rather than for limiting the scope of the present invention. The examples provided below can be used as a guide for further improvements by those of ordinary skill in the art, and do not constitute a limitation of the present invention in any way.
[0060] The experimental methods in the following examples, unless otherwise specified, are all conventional methods, and are performed according to the techniques or conditions described in the literature in the field or according to the product instructions. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial channels.
[0061] The quantitative tests in the following examples were all repeated three times, and the results were averaged.
[0062] In the following examples, the amino acid sequence of the E2 protein of human papillomavirus HPV16 (abbreviated as E2 protein) is shown in SEQ ID NO: 1 from position 1 to 365 from the N-terminus. The nucleotide sequence of the gene encoding the E2 protein (i.e., the E2 gene) is shown in SEQ ID NO: 2 from position 1 to 1095 from the 5' end.
[0063] Example 1. Expression and purification of E2 fusion protein
[0064] 1. Construction of recombinant plasmid pET-28a-HPV16 E2
[0065] 1. After a lot of experiments and exploration, the inventors of the present application artificially synthesized the E2 fusion protein with the amino acid sequence shown in SEQ ID NO: 1 and the nucleotide sequence of the gene encoding the E2 fusion protein (E2 fusion gene). The nucleotide sequence of the E2 fusion gene is shown in SEQ ID NO: 2.
[0066] In SEQ ID NO: 1, from the N-terminus, positions 1 to 365 are E2 protein, positions 366 to 371 are connecting peptide GGSSGG, and positions 372 to 380 are HA tags.
[0067] In SEQ ID NO: 2, from the 5' end, positions 1 to 1095 are E2 genes, positions 1096 to 1113 are genes encoding the connecting peptide GGSSGG, and positions 1114 to 1140 are genes encoding the HA tag.
[0068] Compared with E2 protein, E2 fusion protein only adds a linker peptide GGSSGG and HA tag at the C-terminus. HA tag is a commonly used protein tag, which is derived from the surface antigenic determinant of hemagglutinin of influenza virus. HA tag has little effect on the spatial structure of target protein and is easy to detect. Therefore, after adding the linker peptide GGSSGG and HA tag, the properties of the protein will not change; that is, compared with E2 protein, the properties of E2 fusion protein will not change.
[0069] 2. According to the codon preference of Escherichia coli, the inventors of the present application optimized the nucleotide sequence of the E2 fusion gene. The optimized nucleotide sequence is shown in SEQ ID NO: 3.
[0070] The nucleotide sequence shown in SEQ ID NO: 3 encodes E2 fusion protein. The nucleotide sequence shown in SEQ ID NO: 3 is named E2-YH fusion gene.
[0071] In SEQ ID NO: 3, from the 5' end, positions 1 to 1095 are E2 genes, positions 1096 to 1113 are genes encoding the connecting peptide GGSSGG, and positions 1114 to 1140 are genes encoding the HA tag.
[0072] 3. Recombinant plasmid pET-28a-HPV16 E2 was constructed by Suzhou Jinweizhi Biotechnology Co., Ltd. The recombinant plasmid pET-28a-HPV16 E2 was obtained by replacing the small DNA fragment between the restriction endonucleases Nde I (5') and XhoI (3') of the vector pET-28a (EMD Biosciences) with the E2-YH fusion gene shown in SEQ ID NO: 3, while the other nucleotide sequences remained unchanged.
[0073] The recombinant plasmid pET-28a-HPV16 E2 expresses the E2 fusion protein with the amino acid sequence shown in SEQ ID NO:1.
[0074] 2. Expression and purification of E2 fusion protein
[0075] 1. The recombinant plasmid pET-28a-HPV16 E2 was transformed into Escherichia coli BL21 (DE3) competent cells (Beijing Quanshijin Biotechnology Co., Ltd.) to obtain recombinant Escherichia coli.
[0076] 2. Take 12 shaking tubes, add 4 mL of LB liquid medium (containing kanamycin sulfate (Solebol, K8020) at a final concentration of 50 μg / mL) to each tube, then inoculate each tube with a single clone of the recombinant E. coli obtained in step 1, and culture at 37°C, 200 rpm overnight to obtain culture solution 1. Combine the culture solution 1 (48 mL in total) and pour all into 2 L of LB liquid medium (containing kanamycin sulfate at a final concentration of 50 μg / mL), culture at 37°C, 200 rpm, and obtain an OD 600nm The value of the culture solution 2 is about 0.7. IPTG is added to the culture solution 2 to obtain an induction system; in the induction system, the concentration of IPTG is 0.4 mM. The induction system is cultured at 16°C and 150 rpm for 24 hours, and then centrifuged at 7000 rpm for 10 minutes to collect the bacteria.
[0077] 3. Resuspend the bacteria collected in step 2 with lysis buffer (the amount of lysis buffer used is: 30 mL of lysis buffer for every 1 L of culture solution 2), and then use a low-temperature high-pressure cell disruptor to disrupt them at 4°C (cell disruption pressure 1300 Pa, disrupt 7 times) to obtain a suspension.
[0078] The solutes and concentrations of the lysis buffer are 20 mM Tris-HCl, 500 mM NaCl, 0.5% TritonX-100, 20 mg / L RNaseA, 20 mg / L DNaseI, 10% glycerol, 1 mM DTT and protease inhibitors, the solvent is water, and the pH value is 8.0.
[0079] 4. Take the suspension obtained in step 3, centrifuge it at 4°C and 12000 rpm for 45 min, and collect the supernatant.
[0080] 5. Prepare the binding system. The binding system is 500 μL, consisting of the supernatant collected in step 4, Ni beads (product of QIAGEN, catalog number 1018244) and imidazole. The concentration of imidazole in the binding system is 20 mM.
[0081] 6. Take the binding system prepared in step 5, invert and bind at 4℃ for 4h, then pour the supernatant after binding to Ni beads into the binding column; after the liquid is completely drained, wash twice with solution A, 500μL each time; then wash twice with solution B (to wash away all impurities), 500μL each time; finally, elute the target protein with a total volume of 4mL elution buffer and collect the protein solution.
[0082] The solutes and their concentrations of solution A are 20 mM Tris-HCl, 500 mM NaCl, 0.4 mM DTT and 30 mM imidazole, the solvent is water, and the pH value is 8.0.
[0083] The solutes and their concentrations of solution B were 20 mM Tris-HCl, 500 mM NaCl, 0.4 mM DTT and 60 mM imidazole, the solvent was water, and the pH value was 8.0.
[0084] The solutes and their concentrations of the elution buffer were 20 mM Tris-HCl, 500 mM NaCl, 500 mM imidazole, 1 mM DTT and 10% glycerol, the solvent was water, and the pH value was 8.0.
[0085] 7. The protein solution collected in step 6 was placed in a dialysis bag for dialysis. The details are as follows: first, 1L of protein dialysis solution was used, and magnetic stirring was carried out at 4°C overnight; the next day, a new 1L of protein dialysis solution was replaced, and magnetic stirring was carried out for 4 hours at 4°C; then, a 30kDa ultrafiltration tube was used to concentrate the protein at a low temperature of 4°C, and finally a protein solution with a volume of about 650μL was obtained.
[0086] The solutes and concentrations of the protein dialysate were 20 mM Tris, 100 mM NaCl, 1 mM DTT and 10% glycerol, the solvent was water, and the pH value was 8.0.
[0087] 8. Use polyacrylamide gel electrophoresis (SDS-PAGE) to detect the protein solution obtained in step 7, and the protein loading volume is 20 μL.
[0088] Test results are shown in Figure 1 The results showed that there was a band of E2 fusion protein near the 40-55 kDa position and the purity was high.
[0089] 9. Perform a protein immunoblotting experiment on the protein solution obtained in step 7. The specific steps are as follows:
[0090] (1) Electrophoresis
[0091] The protein solution obtained in step 7 was subjected to gel electrophoresis (SDS-PAGE) with a protein loading volume of 6 μL;
[0092] (2) Transfer
[0093] The electrophoresis tank was placed in an ice bath and 500 mL of electrophoresis solution was added (add appropriate amount of pure water to 14.42 g of glycine, 200 mL of methanol and 3.03 g of Tris base to dissolve, then dilute to 1 L with pure water and store at 4 °C). The transfer clip, gel, filter paper and sponge were assembled and placed in the electrophoresis tank, and the membrane was transferred at a constant current of 200 mA for 90 min.
[0094] (3) Membrane blocking
[0095] Soak the membrane in skim milk solution (add 50 mL of TBST buffer (add appropriate amount of pure water to 12.1 g of Tris base and 40 g of NaCl to dissolve, then adjust the pH to 7.6 with hydrochloric acid, and then dilute to 1 L with pure water to obtain 5×TBS; take 100 mL of 5×TBS, add pure water to dilute to 500 mL, then add 0.5 mL of Tween-20, stir and mix to obtain TBST buffer)
[0096] Incubate at room temperature on a shaker for 30 min.
[0097] (4) Primary antibody incubation
[0098] After blocking, the skim milk was discarded, and the cells were briefly washed with TBST buffer, and His antibody diluent (5% BSA (50 g BSA powder (Solarbio product, catalog number A8010) was dissolved in 1 L TBST buffer) was added to dilute the primary antibody His antibody (Abbkine product, catalog number ABT2050)) and incubated at room temperature on a shaker for 1 h;
[0099] (5) Secondary antibody incubation
[0100] The primary antibody was discarded, and the cells were washed three times with TBST buffer, each wash was placed on a shaker at room temperature for 5 min, and then the secondary antibody IgG anti-mouse (product of Abbkine, catalog number A21010) was added and shaken at room temperature for 2 h;
[0101] (6) Development
[0102] Discard the secondary antibody, then wash three times with TBST buffer, place on a shaker at room temperature for 5 minutes each time for development, dry the liquid on the membrane as much as possible with absorbent paper, then evenly add developer, and then choose the appropriate exposure time for imaging.
[0103] Test results are shown in Figure 2 The results showed that the protein in the protein solution obtained in step 7 was indeed E2 fusion protein.
[0104] After the concentration of the E2 fusion protein in the protein solution was detected, the solution was aliquoted and quickly frozen in liquid nitrogen and stored at -80° C. The concentration of the E2 fusion protein in the protein solution obtained in step 7 was 0.746 mg / mL.
[0105] Example 2: Detection of DNA helicase activity of E2 fusion protein
[0106] Experimental principle: The nucleic acid melting experiment is based on the principle of fluorescence resonance energy transfer. First, the company is commissioned to synthesize complementary single-stranded DNA nucleic acids, and the fluorescent group CY3 and the quenching group BHQ2 are respectively labeled at the ends of the single strands; after receiving the nucleic acids, the complementary single-stranded DNA nucleic acids are annealed to form a double strand. At this time, since CY3 and BHQ2 are relatively close in position, fluorescence resonance energy transfer occurs, and the light emitted by CY3 is absorbed and quenched by BHQ2, and the fluorescence value of the solution is very low; when the E2 fusion protein is added to melt the double strands, CY3 and BHQ2 move away, the fluorescence resonance phenomenon disappears, and the emitted light of CY3 can be detected. As the melting progresses, the fluorescence value of the solution continues to increase.
[0107] The experimental steps are as follows:
[0108] 1. Artificially synthesize ssDNA labeled with CY3 fluorescent group (CY3-ssDNA) and ssDNA labeled with BHQ2 quenching group (BHQ2-ssDNA);
[0109] BHQ2-ssDNA: 5'-AGCACCGTAAAGACGC-BHQ2-3';
[0110] CY3-ssDNA: 5'-CY3-GCGTCTTTACGGTGCTTAAAACAAAACAAACAAAACAAAA-3'.
[0111] 2. After completing step 1, anneal CY3-ssDNA and BHQ2-ssDNA to obtain dsDNA with protruding ends. The specific steps are as follows:
[0112] (1) The ssDNA (CY3-ssDNA or BHQ2-ssDNA) powder was centrifuged at the maximum speed for 2 min in a desktop centrifuge to allow the powder to settle to the bottom of the tube to prevent the loss of powder due to opening the lid; then, annealing buffer was added to dissolve the powder, shaken on an oscillator for about 30 seconds, and centrifuged in a centrifuge for 1 min to obtain a ssDNA stock solution with a concentration of 10 μmol / L.
[0113] The solute and concentration of the annealing buffer were 100 mmol / L KCl and 2 mmol / L MgCl2, and the solvent was pH 7.4, 20 mmol / L Tris-HCl buffer.
[0114] (2) Add CY3-ssDNA master solution and BHQ2-ssDNA master solution to the annealing buffer and mix well to obtain a mixed solution; in the mixed solution, the concentration of CY3-ssDNA and BHQ2-ssDNA is 500mmol / L. Then add the mixed solution to the EP tube, wrap the EP tube with tin foil, and place it in a 95℃ metal bath for 5 minutes. Then turn off the power of the metal bath and cool it naturally to room temperature.
[0115] (3) After completing step (2), add ddH2O to the EP tube to obtain a dsDNA solution.
[0116] 3. After completing step 2, prepare a melting system. The melting system is 100 μL, consisting of 10 μL 10× melting buffer, 10 μL dsDNA solution, 10 μL protein solution obtained in step 7 of Example 1, step 2 (i.e., the experimental group with E2 fusion protein added) or protein dialysate (as a control group), 5 μL ATP, 5 μL competitor ssDNA solution and water. In the melting system, the concentration of dsDNA is 500nmol / L, the concentration of ATP is 100mmol / L, and the concentration of competitor ssDNA is 10μmol / L.
[0117] competitor ssDNA: 5'-GCGTCTTTACGGTGCT-3'.
[0118] The solutes and their concentrations of the 10× melting buffer are 10mmol / L NaCl, 5mmol / L MgCl2 and 0.1g / L BSA, and the solvent is pH 7.4, 20mmol / L Tris-HCl buffer.
[0119] 4. After completing step 3, add the denaturation system to a white 96-well plate and cover it with tin foil, then place the plate under an ELISA reader for reading (the parameters of the ELISA reader are set to: excitation light 550nm, emission light 620nm, cut off value 610nm); the ELISA reader continuously detects changes in the fluorescence value of the solution at a time interval of 1min until the reaction is carried out for 1 hour.
[0120] 5. After completing step 4, perform data processing, specifically: subtract the initial fluorescence value (F t -F0) were fitted with nonlinear regression using GraphPad prism, with the horizontal axis representing time and the vertical axis representing F t -F0.
[0121] Test results are shown in Figure 3 (Control is the control group, and E2 fusion protein is the experimental group). The results showed that E2 fusion protein has DNA helicase activity.
[0122] Example 3: E2 fusion protein can be used as a target for screening anti-human papillomavirus drugs (such as podophyllotoxin)
[0123] Podophyllotoxin (PTOX) is an aromatic tetralin lignan derived from Podophyllum plants such as Illustris odoratus, Helena serrata and Psoralea corylifolia. Current studies suggest that podophyllotoxin has anti-human papillomavirus activity.
[0124] 1. Preparation of podophyllotoxin solutions of different concentrations
[0125] The podophyllotoxin stock solution was diluted with DMSO to obtain podophyllotoxin solution 1 with a concentration of 1 mM, podophyllotoxin solution 2 with a concentration of 0.1 mM, and podophyllotoxin solution 3 with a concentration of 0.01 mM, respectively.
[0126] Podophyllotoxin stock solution: 482.6 μL DMSO was added to 20 mg of podophyllotoxin powder (product of Chemical book, CAS No. 518-28-5), and the mixture was vortexed to mix well to obtain a podophyllotoxin stock solution with a concentration of 100 mM.
[0127] 2. Incubate 3 μL of the protein solution obtained in step 7 of Example 1, step 2, with 5 μL of DMSO to obtain E2 fusion protein + DMSO complex 1. Incubate 3 μL of the protein solution obtained in step 7 of Example 1, step 2, with 5 μL of podophyllotoxin solution 1 to obtain E2 fusion protein + podophyllotoxin complex 2. Incubate 3 μL of the protein solution obtained in step 7 of Example 1, step 2, with 5 μL of podophyllotoxin solution 2 to obtain E2 fusion protein + podophyllotoxin complex 3. Incubate 3 μL of the protein solution obtained in step 7 of Example 1, step 2, with 5 μL of podophyllotoxin solution 3 to obtain E2 fusion protein + podophyllotoxin complex 4.
[0128] 3. Prepare negative control reaction system, E2 protein reaction system, E2+0.5μM podophyllotoxin reaction system, E2+5μM podophyllotoxin reaction system and E2+50μM podophyllotoxin reaction system. The details are as follows:
[0129] The negative control reaction system was 100 μL, consisting of 56 μL ddH2O, 10 μL 10× melting buffer, 10 μL dsDNA solution, 10 μL protein dialyzate, 5 μL DMSO, 5 μL competitor ssDNA solution, and 4 μL ATP. In the negative control reaction system, the concentration of dsDNA was 500 nmol / L, the concentration of ATP was 100 mmol / L, and the concentration of competitor ssDNA was 10 μmol / L.
[0130] The E2 protein reaction system is 100 μL, consisting of 56 μL ddH2O, 10 μL 10× melting buffer, 10 μL dsDNA solution, 8 μL E2 fusion protein + DMSO complex 1, 7 μL protein dialyzate, 5 μL competitor ssDNA solution and 4 μL ATP. In the E2 protein reaction system, the concentration of dsDNA is 500 nmol / L, the concentration of ATP is 100 mmol / L, and the concentration of competitor ssDNA is 10 μmol / L.
[0131] The E2+0.5μM podophyllotoxin reaction system is 100μL, consisting of 56μL ddH2O, 10μL 10× melting buffer, 10μL dsDNA solution, 8μL E2 fusion protein + podophyllotoxin complex 4, 7μL protein dialyzate, 5μL competitor ssDNA solution and 4μL ATP. In the E2+0.5μM podophyllotoxin reaction system, the concentration of dsDNA is 500nmol / L, the concentration of ATP is 100mmol / L, and the concentration of competitor ssDNA is 10μmol / L.
[0132] The E2+5μM podophyllotoxin reaction system is 100μL, consisting of 56μL ddH2O, 10μL 10× melting buffer, 10μL dsDNA solution, 8μL E2 fusion protein + podophyllotoxin complex 3, 7μL protein dialyzate, 5μL competitor ssDNA solution and 4μL ATP. In the E2+0.5μM podophyllotoxin reaction system, the concentration of dsDNA is 500nmol / L, the concentration of ATP is 100mmol / L, and the concentration of competitor ssDNA is 10μmol / L.
[0133] The E2+50μM podophyllotoxin reaction system is 100μL, consisting of 56μL ddH2O, 10μL 10× melting buffer, 10μL dsDNA solution, 8μL E2 fusion protein + podophyllotoxin complex 2, 7μL protein dialyzate, 5μL competitor ssDNA solution and 4μL ATP. In the E2+0.5μM podophyllotoxin reaction system, the concentration of dsDNA is 500nmol / L, the concentration of ATP is 100mmol / L, and the concentration of competitor ssDNA is 10μmol / L.
[0134] The 10× melting buffer, dsDNA solution, protein dialyzate and ssDNA solution are the same as those in Example 2.
[0135] 4. After completing step 3, add the negative control reaction system, E2 protein reaction system, E2+0.5μM podophyllotoxin reaction system, E2+5μM podophyllotoxin reaction system and E2+50μM podophyllotoxin reaction system to a white 96-well plate and cover them with tin foil, then place the plate under an enzyme reader for reading (the parameters of the enzyme reader are set to: excitation light 550nm, emission light 620nm, cut off value 610nm); the enzyme reader continuously detects changes in the fluorescence value of the solution at a time interval of 1min until the reaction is carried out for 1 hour.
[0136] 5. After completing step 4, perform data processing, specifically: subtract the initial fluorescence value (F t -F0) were fitted with nonlinear regression using GraphPad prism, with the horizontal axis representing time and the vertical axis representing F t -F0.
[0137] Test results are shown in Figure 4 (control is the negative control reaction system, E2 protein is the E2 protein reaction system, E2 protein + 0.5 μM podophyllotoxin is the E2 + 0.5 μM podophyllotoxin reaction system, E2 protein + 5 μM podophyllotoxin is the E2 + 5 μM podophyllotoxin reaction system, and E2 protein + 50 μM podophyllotoxin is the E2 + 50 μM podophyllotoxin reaction system). The results showed that E2 fusion protein can be used as a target for screening anti-human papillomavirus drugs (such as podophyllotoxin) and podophyllotoxin is an E2 fusion protein DNA helicase inhibitor.
[0138] Example 4: Molecular docking of podophyllotoxin and E2 protein
[0139] In order to further clarify the specific region where podophyllotoxin binds to E2 protein, the inventors of the present application first predicted the whole protein structure on aphfold3 (URL: https: / / golgi.sandbox.google.com / welcome) (there is no whole protein structure of E2 protein yet) to obtain the structure of E2 protein. Then, the Auto-dock vina software (URL: https: / / vina.scripps.edu / ) was used to perform molecular docking between E2 protein and podophyllotoxin.
[0140] For specific binding sites, see Figure 5 The results showed that E2 protein and podophyllotoxin had a high binding affinity.
[0141] It can be seen that E2 protein provides a definite new target for the discovery of anti-human papillomavirus drugs.
[0142] The present invention has been described in detail above. For those skilled in the art, without departing from the purpose and scope of the present invention, and without the need to carry out unnecessary experimental conditions, the present invention can be implemented in a wide range under equivalent parameters, concentrations and conditions. Although the present invention provides specific embodiments, it should be understood that the present invention can be further improved. In a word, according to the principles of the present invention, the application is intended to include any changes, uses or improvements to the present invention, including departure from the disclosed scope in the application, and changes made with conventional techniques known in the art.
Claims
1. E2 fusion protein, which is a1) or a2) or a3) or a4) as follows: a1) is formed by fusion of E2 protein and a tag; the amino acid sequence of the E2 protein is shown in SEQ ID NO: 1 from position 1 to position 365 from the N-terminus; a2) a fusion protein obtained by connecting a tag to the N-terminus and / or C-terminus of the protein shown in a1); a3) a protein having helicase activity obtained by substituting and / or deleting and / or adding one or more amino acid residues in the amino acid sequence of the protein shown in a1) or a2); a4) A protein having an amino acid sequence homology of 80% or more to the protein shown in a1) or a2) and having helicase activity.
2. The E2 fusion protein according to claim 1, characterized in that: In a1), the amino acid sequence of the E2 fusion protein is shown in SEQ ID NO:
1.
3. A nucleic acid molecule encoding the E2 fusion protein according to claim 1 or 2.
4. The nucleic acid molecule according to claim 3, characterized in that: The nucleic acid molecule is a DNA molecule as shown in b1) or b2) or b3) or b4) below: b1) the coding region is a DNA molecule shown in SEQ ID NO: 2 or SEQ ID NO: 3; b2) the nucleotide sequence is a DNA molecule shown in SEQ ID NO: 2 or SEQ ID NO: 3; b3) a DNA molecule having 75% or more homology with the nucleotide sequence defined in b1) or b2) and encoding the E2 fusion protein of claim 1 or 2; b4) A DNA molecule that hybridizes with the nucleotide sequence defined in b1) or b2) under stringent conditions and encodes the E2 fusion protein of claim 1 or 2.
5. An expression cassette, recombinant vector or recombinant microorganism containing the nucleic acid molecule according to claim 3 or 4.
6. Use of the E2 protein of claim 1, the E2 fusion protein of claim 1 or 2, or the nucleic acid molecule of claim 3 or 4, wherein the method comprises the following c1) or c2): c1) as a helicase; c2) preparing helicase.
7. The use according to claim 6, characterized in that: The helicase is a DNA helicase; Preferably, the substrate of the DNA helicase is dsDNA.
8. Use of the E2 protein of claim 1, the E2 fusion protein of claim 1 or 2, or the nucleic acid molecule of claim 3 or 4, as follows d1) or d2): d1) Screening of anti-human papillomavirus drugs; d2) as a target for screening anti-human papillomavirus drugs.
9. A method for screening anti-human papillomavirus drugs, comprising detecting whether the drug to be tested can reduce the helicase activity of the E2 protein described in claim 1 or the E2 fusion protein described in claim 1 or 2, and then making the following judgment: if the drug to be tested can reduce the helicase activity of the E2 protein described in claim 1 or the E2 fusion protein described in claim 1 or 2, the drug to be tested is or is suspected to be an anti-human papillomavirus drug; if the drug to be tested cannot reduce the helicase activity of the E2 protein described in claim 1 or the E2 fusion protein described in claim 1 or 2, the drug to be tested is not or is not suspected to be an anti-human papillomavirus drug.
10. Use of podophyllotoxin in reducing the helicase activity of the E2 protein of claim 1 or the E2 fusion protein of claim 1 or 2.
Citation Information
Patent Citations
Methods kits and compositions for diagnosing papillomavirus infection
US5821048A
